Salvagno Ralph T 4
4 · PetLife Pharmaceuticals, Inc. · Filed Mar 2, 2018
Insider Transaction Report
Form 4
Salvagno Ralph T
DirectorChief Executive Officer
Transactions
- Award
Common Stock
2017-08-17$0.06/sh+5,000,000$300,000→ 17,450,000 total(indirect: By LLC) - Other
Common Stock
2017-08-17−1,250,000→ 12,450,000 total(indirect: By LLC) - Other
Series A Preferred Stock
2017-08-17+1,250,000→ 1,250,000 total(indirect: By LLC)
Footnotes (2)
- [F1]Conversion of common stock into Series A preferred stock on a 1:1 basis.
- [F2]Accrued compensation converted into common stock at a conversion rate of $0.06/share.